Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589690 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL25343707 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL20767976 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL20404252 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL26892208 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL2861049 | 0.97 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL13153692 | 0.96 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL13153693 | 0.95 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL13153658 | 0.90 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL2868243 | 0.89 | SLC5A2 (0.78) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724042-A1 | METHOD FOR IMPROVING THE INGESTION OF A LIQUID OR VISCOUS SUBSTANCE | Ceva Santé Animale (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4676494-A1 | SYSTEMS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-01-14 | — | — | EP | claimed |
| WO-2025217520-A1 | TREATING CHRONIC KIDNEY DISEASE WITH A COMBINATION OF SLC6A19 AND SGLT2 INHIBITORS | JNANA THERAPEUTICS INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-12397009-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-08-26 | — | — | US | claimed |
| EP-4531810-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2025-04-09 | — | — | EP | claimed |
| CN-119110722-A | Aqueous pharmaceutical composition comprising an SGLT-2 inhibitor | 勃林格殷格翰动物保健有限公司 | 2024-12-10 | — | — | CN | claimed |
| US-20240398845-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-12-05 | — | — | US | claimed |
| US-20240390332-A1 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-11-28 | — | — | US | claimed |
| CN-102316875-A | SGLT-2 inhibitors for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance or hyperglycemia | BOEHRINGER INGELHEIM INT | 2012-01-11 | — | — | CN | claimed |
| EP-2396005-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | Boehringer Ingelheim International GmbH (DE) | 2011-12-21 | — | — | EP | claimed |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | claimed |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | claimed |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| WO-2010092123-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | WO | claimed |
| US-7776830-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-17 | — | — | US | claimed |
| CN-101784270-A | Pharmaceutical compositions comprising glucopyranosyl-substituted benzene derivatives | BOEHRINGER INGELHEIM INT | 2010-07-21 | — | — | CN | claimed |
| EP-2187879-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12397009-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | DPP4, SLC5A1, DPP7 | SLC5A2 5/4885SLC5A1 2/4885 |
| US-20240398845-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, UGT1A4, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885 |
| US-20240390332-A1 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | SLC5A2, SLC5A1, REN | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.